Risk of prostate cancer in relation to polymorphisms of metabolic genes

Epidemiologic Reviews

Volumn 23, Issue 1, 2001, Pages 30-35

  Chen, C ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CORRELATION FUNCTION; DNA POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR;

EID: 0034801572     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a000793     Document Type: Review

References (85)

1. Environmental and heritable factors in the causation of cancer - Analyses of cohorts of twins from Sweden, Denmark, and Finland
2. Mendelian inheritance of familial prostate cancer
3. Genetic differences in susceptibility to chemically induced myelotoxicity and leukemia
4. Human Ah receptor (AHR) gene: Localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility
5. Regulation of the mammalian cytochrome P1-450 (CYP1A1) gene
6. The control of cytochrome P-450 gene expression by dioxin
7. Human AH locus polymorphism and cancer: Inducibility of CYP1A1 and other genes by combustion products and dioxin
8. The catalytic activity of four expressed human cytochrome P450s towards benzo[a]pyrene and the isomers of its proximate carcinogen
9. Expression of modified human cytochrome P450 1A1 in Escherichia coli: Effects of 5′ substitution, stabilization, purification, spectral characterization, and catalytic properties
10. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene
11. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene
12. A novel CYP1A1 gene polymorphism in African-Americans
13. A C4887A polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages, and impact on lung cancer susceptibility
14. Functional significance of different human CYP1A1 genotypes
15. The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene
16. Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan
17. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
18. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
19. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
20. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer
21. Genetic differences in drug disposition
22. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism
23. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6
24. Nomenclature for human CYP2D6 alleles
25. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
26. Debrisoquine hydroxylase (CY2D6) and prostate cancer
27. Expression in human prostate of drug- and carcinogen-metabolizing enzymes: Association with prostate cancer risk
28. Cytochrome P-450 3A4: Regulation and role in drug metabolism
29. 16α-hydroxylation of estrone by human cytochrome P4503A4/5
30. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region
31. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
32. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: Ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191
33. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients
34. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
35. Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
36. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
37. Intracellular binding and transport of hormones and xenobiotics by glutathione-S-transferases
38. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: A follow up study
39. Glutathione S-transferases as risk factors in prostate cancer
40. Glutathione S-transferase-mu (GSTM1) and -theta (GS1T1) genotypes in the etiology of prostate cancer
41. The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: Genotype-environment interactions with smoking
42. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma
43. Differences in stereoselectivity and catalytic efficiency of three human glutathione transferases in the conjugation of glutathione with 7β,8α-dihydroxy-9α,10α-oxy-7,8,9,10- tetrahydrobenzo(a)pyrene
44. Glutathione S transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma
45. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis
46. Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue
47. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer
48. Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7-β,8-α-dihydroxy-9-α, 10-α-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene
49. Mechanism of differential catalytic efficiency of two polymorphic forms of human glutathione S-transferase P1-1 in the glutathione conjugation of carcinogenic diol epoxide of chrysene
50. Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105
51. Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution
52. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties
53. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase pi gene variants: Evidence for differential catalytic activity of the encoded proteins
54. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer
55. Distribution of ethylene oxide in human blood and its implications on biomonitoring
56. A comparative investigation of the metabolism of methyl bromide and methyl iodide in human erythrocytes
57. Metabolism of dichloromethane (methylene chloride) to formaldehyde in human erythrocytes: Influence of polymorphism of glutathione transferase theta (GST T1-1)
58. Conjugation of carcinogens by theta class glutathione s-transferases: Mechanisms and relevance to variations in human risk
59. Susceptibility to endometrial cancer: Influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci
60. Breast cancer and CYPlal, GSTM1, and GSTT1 polymorphisms: Evidence of a lack of association in Caucasians and African Americans
61. Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia
62. Glutathione S transferase-theta (GSTT1) genetic polymorphism among Chinese, Malays, and Indians in Singapore
63. Gene deletion of glutathione S-transferase theta: Correlation with induced genetic damage and potential role in endogenous mutagenesis
64. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases
65. Arylamine N-acetyltransferase activity in man
66. Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes
67. N-acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium
68. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: Application to metabolic epidemiology
69. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans
70. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene
71. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California
72. Polymorphism of human acetyltransferases
73. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity
74. Human acetyltransferase polymorphisms
75. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
76. N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development
77. DT-diaphorase: Purification, properties, and function
78. NAD(P)H:quinone oxidoreductase 1 reduces the mutagenicity of DNA caused by NADPH:P450 reductase-activated metabolites of benzo(a)pyrene quinones
79. Metabolic basis of benzene toxicity
80. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells
81. Human FAD-dependent NAD(P)H diaphorase
82. NAD(P)H: Quinone oxidoreductase gene expression in human colon carcinoma cells: Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity
83. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity
84. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy
85. 609 C→T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia